homemarket NewsZydus Lifesciences gets USFDA nod for drug used for treatment of type 2 diabetes mellitus patients

Zydus Lifesciences gets USFDA nod for drug used for treatment of type 2 diabetes mellitus patients

Zydus Lifesciences Share Price: The pharma company said Zituvimet has undergone quality testing for Nitrosamines and potential genotoxic impurities as per the present USFDA standards. The new product is also compliant with present USFDA standards of Nitrosamines in Sitagliptin containing products.

Profile image

By CNBCTV18.com Nov 6, 2023 12:04:58 PM IST (Published)

Listen to the Article(6 Minutes)
2 Min Read
Zydus Lifesciences gets USFDA nod for drug used for treatment of type 2 diabetes mellitus patients
Zydus Lifesciences on Monday, November 6, said it has received the final approval from the United States Food and Drug Administration (USFDA) for Zituvimet to treat adult patients with type 2 diabetes mellitus.

Share Market Live

View All

Zituvimettm tablets in the strength of 50 mg/500 mg and 50 mg/1000 mg comprise active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, Zydus Lifesciences said in a stock exchange filing. The new drug is used to improve glycemic control in adults with type 2 diabetes mellitus.
The pharma company said Zituvimet has undergone quality testing for Nitrosamines and potential genotoxic impurities as per the present USFDA standards. The new product is also compliant with present USFDA standards of Nitrosamines in Sitagliptin containing products.
Zydus Lifesciences share price, Zydus Lifesciences share, Zydus Lifesciences USFDA approval, Zydus Lifesciences type2 diabetes, zydus lifesciences stock, diabetes, diabetes drugs, diabetes treatment,
According to IQVIA data, the US market for DPP-IV inhibitors and their combinations is $10 billion at the 12 months ended August 2023.
"The Zituvimet approval further builds on our previous approval of Zituvimet (Sitagliptin) and offers an increased accessibility and affordability to healthcare systems with regard to prescription drugs for type II diabetes,” Sharvil Patel, the managing director of Zydus Lifesciences, said.
The Ahmedabad-based pharma major manufactures and markets a broad range of active pharmaceutical ingredients (API) and formulations. The Zydus group has research facilities across Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim.
In September, Zydus Lifesciences received an establishment inspection report (EIR) from the USFDA for its facility at Pharmez in Ahmedabad with zero observations.
Shares of Zydus Lifesciences were trading 0.3% higher at ₹586.35 apiece on BSE at 9:34am.

Most Read

Share Market Live

View All
Top GainersTop Losers
CurrencyCommodities
CurrencyPriceChange%Change